Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients

• Published in: Journal of hepatology 1996-08, Vol.25 (2), p.212-217
• Main Authors: Artini, Marco, Natoli, Clara, Tinari, Nicola, Costanzo, Antonio, Marinelli, Rossana, Balsano, Clara, Porcari, Patrizia, Angelucci, Domenico, D'Egidio, Maurizia, Levrero, Massimo, Iacobelli, Stefano
• Format: Article
• Language: English
• Subjects: 90K/MAC-2 BP; Adult; Aged; Antigens, Neoplasm; Biological and medical sciences; Biomarkers, Tumor; Carrier Proteins - blood; Carrier State - blood; Chronic Disease; Chronic hepatitis; Cohort Studies; Female; Forecasting; Glycoproteins - blood; HCV genotypes; Hepatitis B - blood; Hepatitis B - physiopathology; Hepatitis B - therapy; Hepatitis C - blood; Hepatitis C - physiopathology; Hepatitis C - therapy; Humans; Immunomodulators; Interferon-alpha - therapeutic use; Lipoproteins - blood; Male; Medical sciences; Middle Aged; Neoplasm Proteins - blood; Pharmacology. Drug treatments; Response predictors; Treatment Failure; α-IFN therapy
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/S0168-8278(96)80076-6

Background: The clinical outcome of hepatitis virus infections is thought to depend on the complex interplay between the host immune response profile and virus factors. 90K/MAC-2 BP is a novel member of the Scavenger Receptor Cysteine Rich protein superfamily that functions as a molecular alarm signal for the cellular immune system against both cancer cells and virus infections. Methods: To assess the significance and the potential clinical usefulness of testing for serum levels of 90K/MAC-2 BP in chronic viral hepatitis patients we studied 115 consecutive patients with chronic HCV hepatitis, 28 HBsAg chronic hepatitis patients, 12 asymptomatic HCV carriers and 11 asymptomatic HBV carriers. 103 out of the 115 HCV patients have been treated with recombinant α2a-interferon at the dose of 3 Mega Units (MU) t.i.w. for 6 months followed by 1.5 MU t.i.w. for 6 months, and have been followed up for a further 12 months. Serum levels of 90K/MAC-2 BP were measured by an immunoradiometric assay based on the specific SP-2 monoclonal antibody. Results and Conclusions: Serum 90K/MAC-2 BP levels are increased in chronic vital hepatitis patients, being significantly higher in HCV than in HBV patients. In chronic HCV hepatitis, serum 90K/MAC-2 BP levels are related to both the degree of disease severity and duration of infection. Moreover, elevated 90K/MAC-2 BP serum levels are an independent predictor of failure to respond to α-interferon treatment in a cohort of community-acquired chronic hepatitis C patients.